Discovery of Acylsulfonohydrazide-Derived Inhibitors of the Lysine Acetyltransferase, KAT6A, as Potent Senescence-Inducing Anti-Cancer Agents
摘要:
A high-throughput screen designed to discover new inhibitors of histone acetyltransferase KAT6A uncovered CTX-0124143 (1), a unique aryl acylsulfonohydrazide with an IC50 of 1.0 mu M. Using this acylsulfonohydrazide as a template, we herein disclose the results of our extensive structure-activity relationship investigations, which resulted in the discovery of advanced compounds such as 55 and 80. These two compounds represent significant improvements on our recently reported prototypical lead WM-8014 (3) as they are not only equivalently potent as inhibitors of KAT6A but are less lipophilic and significantly more stable to microsomal degradation. Furthermore, during this process, we discovered a distinct structural subclass that contains key 2-fluorobenzenesulfonyl and phenylpyridine motifs, culminating in the discovery of WM-1119 (4). This compound is a highly potent KAT6A inhibitor (IC50 = 6.3 nM; K-D = 0.002 mu M), competes with Ac-CoA by binding to the Ac-CoA binding site, and has an oral bioavailability of 56% in rats.
Discovery of Acylsulfonohydrazide-Derived Inhibitors of the Lysine Acetyltransferase, KAT6A, as Potent Senescence-Inducing Anti-Cancer Agents
摘要:
A high-throughput screen designed to discover new inhibitors of histone acetyltransferase KAT6A uncovered CTX-0124143 (1), a unique aryl acylsulfonohydrazide with an IC50 of 1.0 mu M. Using this acylsulfonohydrazide as a template, we herein disclose the results of our extensive structure-activity relationship investigations, which resulted in the discovery of advanced compounds such as 55 and 80. These two compounds represent significant improvements on our recently reported prototypical lead WM-8014 (3) as they are not only equivalently potent as inhibitors of KAT6A but are less lipophilic and significantly more stable to microsomal degradation. Furthermore, during this process, we discovered a distinct structural subclass that contains key 2-fluorobenzenesulfonyl and phenylpyridine motifs, culminating in the discovery of WM-1119 (4). This compound is a highly potent KAT6A inhibitor (IC50 = 6.3 nM; K-D = 0.002 mu M), competes with Ac-CoA by binding to the Ac-CoA binding site, and has an oral bioavailability of 56% in rats.
[EN] KAT6 INHIBITOR METHODS AND COMBINATIONS FOR CANCER TREATMENT<br/>[FR] MÉTHODES ET COMBINAISONS D'INHIBITEURS DE KAT6 POUR LE TRAITEMENT DU CANCER
申请人:PFIZER
公开号:WO2022013369A1
公开(公告)日:2022-01-20
This invention relates to methods and combination therapies for treating cancer by administering a KAT6 inhibitor to a patient in need therof.
本发明涉及通过向需要治疗的患者施用KAT6抑制剂来治疗癌症的方法和联合疗法。
Aryl sulfonohydrazides
申请人:MONASH UNIVERSITY
公开号:US10829446B2
公开(公告)日:2020-11-10
Compound of formula I:
wherein:
A is selected from:
(i)
where RF1 is H or F;
(ii)
(iii) a N-containing C6 heteroaryl group; and
B is
where X1 is either CRF2 or N, where RF2 is H or F; X2 is either CR3 or N, where R3 is selected from H, Me, Cl, F OMe; X3 is either CH or N; X4 is either CRF3 or N, where RF3 is H or F; where only one or two of X1, X2, X3 and X4 may be N; and
R4 is selected from I, optionally substituted phenyl, optionally substituted C5-6 heteroaryl; optionally substituted C1-6 alkyl and optionally substituted C1-6 alkoxy, which are useful in the treatment of a condition ameliorated by the inhibition of MOZ.
式 I 的化合物:
其中
A 选自
(i)
其中 RF1 为 H 或 F;
(ii)
(iii) 含 N 的 C6 杂芳基;以及
B 是
其中 X1 是 CRF2 或 N,其中 RF2 是 H 或 F;X2 是 CR3 或 N,其中 R3 选自 H、Me、Cl、F OMe;X3 是 CH 或 N;X4 是 CRF3 或 N,其中 RF3 是 H 或 F;其中 X1、X2、X3 和 X4 中只有一个或两个可以是 N;以及
R4 选自 I、任选取代的苯基、任选取代的 C5-6 杂芳基、任选取代的 C1-6 烷基和任选取代的 C1-6 烷氧基,它们可用于治疗通过抑制 MOZ 而改善的病症。
ARYL SULFONOHYDRAZIDES
申请人:MONASH UNIVERSITY
公开号:US20180222857A1
公开(公告)日:2018-08-09
Compound of formula I:
wherein:
A is selected from:
(i)
where R
F1
is H or F;
(ii)
(iii) a N-containing C
6
heteroaryl group; and
B is
where X
1
is either CR
F2
or N, where R
F2
is H or F; X
2
is either CR
3
or N, where R
3
is selected from H, Me, Cl, F OMe; X
3
is either CH or N; X
4
is either CR
F3
or N, where R
F3
is H or F; where only one or two of X
1
, X
2
, X
3
and X
4
may be N; and R
4
is selected from I, optionally substituted phenyl, optionally substituted C
5-6
heteroaryl; optionally substituted C
1-6
alkyl and optionally substituted C
1-6
alkoxy, which are useful in the treatment of a condition ameliorated by the inhibition of MOZ.
Discovery of Acylsulfonohydrazide-Derived Inhibitors of the Lysine Acetyltransferase, KAT6A, as Potent Senescence-Inducing Anti-Cancer Agents
作者:Daniel L. Priebbenow、David J. Leaver、Nghi Nguyen、Benjamin Cleary、H. Rachel Lagiakos、Julie Sanchez、Lian Xue、Fei Huang、Yuxin Sun、Prashant Mujumdar、Ramesh Mudududdla、Swapna Varghese、Silvia Teguh、Susan A. Charman、Karen L. White、David M. Shackleford、Kasiram Katneni、Matthew Cuellar、Jessica M. Strasser、Jayme L. Dahlin、Michael A. Walters、Ian P. Street、Brendon J. Monahan、Kate E. Jarman、Helene Jousset Sabroux、Hendrik Falk、Matthew C. Chung、Stefan J. Hermans、Natalie L. Downer、Michael W. Parker、Anne K. Voss、Tim Thomas、Jonathan B. Baell
DOI:10.1021/acs.jmedchem.9b02071
日期:2020.5.14
A high-throughput screen designed to discover new inhibitors of histone acetyltransferase KAT6A uncovered CTX-0124143 (1), a unique aryl acylsulfonohydrazide with an IC50 of 1.0 mu M. Using this acylsulfonohydrazide as a template, we herein disclose the results of our extensive structure-activity relationship investigations, which resulted in the discovery of advanced compounds such as 55 and 80. These two compounds represent significant improvements on our recently reported prototypical lead WM-8014 (3) as they are not only equivalently potent as inhibitors of KAT6A but are less lipophilic and significantly more stable to microsomal degradation. Furthermore, during this process, we discovered a distinct structural subclass that contains key 2-fluorobenzenesulfonyl and phenylpyridine motifs, culminating in the discovery of WM-1119 (4). This compound is a highly potent KAT6A inhibitor (IC50 = 6.3 nM; K-D = 0.002 mu M), competes with Ac-CoA by binding to the Ac-CoA binding site, and has an oral bioavailability of 56% in rats.